Navigation Links
Arena Submits Response to FDA Complete Response Letter for Lorcaserin
Date:1/3/2012

information also includes data and analyses from activities intended to address tumors observed in a two-year lorcaserin rat carcinogenicity study, cell culture experiments intended to further refine serotonin subtype 2 receptor activity and rat studies designed to further assess abuse potential. It is important to note that the FDA may analyze or weigh the data differently than Arena and Eisai.Conference Call and WebcastArena will host a conference call and webcast to discuss the response to the lorcaserin CRL, including results from the studies conducted to investigate the mechanism underlying mammary tumors that were observed in female rats, at 5:30 p.m. Eastern Time (2:30 p.m. Pacific Time) today. An overview of the results from the rat mechanistic studies is also available in a Form 8-K that Arena filed today with the Securities and Exchange Commission.

The conference call may be accessed by dialing 877.643.7155 for domestic callers and 914.495.8552 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals' Lorcaserin Conference Call." The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About LorcaserinLorcaserin is an investigational drug candidate intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition. Lorcaserin is a new chemical entity that is believed to act as a selective serotonin 2C receptor agonist. The serotonin 2C receptor is expressed in the brain, including the hypothalamus, an area believ
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Arena Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
2. Arena Pharmaceuticals to Present at the Piper Jaffray 23rd Annual Health Care Conference
3. Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
4. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
5. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
6. Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results
7. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
8. Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
9. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
10. Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
11. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW ... for operable and inoperable solid tumor cancers, announced today that ... th Annual Phacilitate Immunotherapy Forum in Washington ... will take place on January 26 at 10:30 a.m. EST ...
(Date:1/23/2015)... a third of reproductive-aged women enrolled in Medicaid, and more ... prescription for an opioid pain medication each year during 2008-2012, ... Weekly Report (MMWR). Opioids are typically prescribed ... They are also found in some prescription cough medications. The ...
(Date:1/23/2015)... Feffer LLP ( www.hfesq.com ) is investigating potential claims ... or the "Company") (NASDAQ: ADXS ), concerning ... shareholders. On January 21, 2015, an article ... had misrepresented the clinical data for its ADXS-HPV drug ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... announces that a new market research report is available ... http://www.reportlinker.com/p0357031/Regenerative-Medicine-Markets.html Regenerative ... human tissue by using laboratory-grown or therapeutically-induced human tissue ... the ability to repair or replace damaged human tissue ...
... YORK, Dec. 29, 2010 Reportlinker.com announces that ... its catalogue: 2010-2015 In-depth Research ... http://www.reportlinker.com/p0356862/2010-2015-In-depth-Research-Report-on-China-Sodium-Fluoride-Industry.html Report ... State Statistical Bureau, General Administration of Custom, Ministry ...
Cached Medicine Technology:Reportlinker Adds Regenerative Medicine Markets 2Reportlinker Adds 2010-2015 In-depth Research Report on China Sodium Fluoride Industry 2
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put ... muscle by up to 30lbs in less than 12 weeks ... Stan Stevenson, prompting an investigative review. , “Our Incredible ... diet formula that allows the body to pack on a ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2
... cut bleeding time in half, but use in humans is ... Hoping to improve on nature, researchers have built and tested ... used in trauma or other cases where blood just won,t ... material that is used in degradable stitches, which dissolve in ...
... determining factor for use, expert says, , WEDNESDAY, Dec. 16 ... less likely to die when they receive an implantable cardioverter ... people, ages 65 to 85, who were eligible for the ... the heart,s pumping ability) of 35 percent or less. , ...
... Dec. 16 Medical travel facilitator Companion Global Healthcare ... into its network of international hospitals that treat American ... U.S. facilities. , The announcement means Companion Global Healthcare ... its individual clients and employer group members who seek ...
... FRANCISCO, Dec. 16 Quantros, Inc., a leading provider ... for the healthcare industry, announces the creation of a ... industry veteran Michael Tulloch, MBA, as Director of IT ... Marlborough, MA office. , "The expansion into IT services ...
... happens when the families of sick and dying hospitalized children ... How do pediatricians respond to such personal requests? While increasing ... patients and families cope with serious illness, a new study ... who raise the issue of prayer, not the doctors themselves. ...
... Dec. 16 Tyco International Ltd. (NYSE: TYC ... election to the Tyco Board of Directors at the company,s ... 55, is Senior Vice President of the Global Technology Services ... has worldwide responsibility for IBM,s Global Services business operations consisting ...
Cached Medicine News:Health News:Synthetic Platelets Put the Brakes on Blood Loss 2Health News:Synthetic Platelets Put the Brakes on Blood Loss 3Health News:Implanted Defibrillator Might Extend Life 2Health News:Hospitals in Puerto Rico Join Companion Global Healthcare's Network 2Health News:Safety and Quality Software Developer Quantros, Inc. Launches Healthcare IT Consulting Division 2Health News:Prayer on the hospital floor 2Health News:Tyco International Files Preliminary Proxy Proposing Election of New Director 2
Midstream Catch Kits...
... is a portable, noninvasive ultrasound instrument that ... to use, and quickly provides accurate results. ... use the BladderScan® to obtain a precise ... BladderScan® supplies the information that caregivers need ...
... Mobile BladderScan® BVI 6400 calculates bladder ... technology. V-MODE® ultrasound is accurate, fast, ... the BladderScan® measures ultrasonic reflections within ... creates a 3-dimensional image of the ...
... The Titan™ Inflatable Penile Prosthesis ... designed to be surgically implanted ... management of erectile dysfunction (also ... provides the patient with voluntary ...
Medicine Products: